Mirapex LA

Pramipexole

Method of action: Antiparkinsonian, Dopaminergic

Treatment option: Parkinson Disease, Restless Legs Syndrome

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirapex LA

Quick Facts

Property	Description
Active ingredient	Pramipexole
Form	Extended-Release Tablet
Pharmacological class	Non-Ergot Dopamine Agonist
General Purpose	Restoration of Dopaminergic System Balance
Origin	Synthetic Compound

What is Mirapex LA? A Non-Ergot Dopamine Agonist

Mirapex LA is the trade name for the prescription-only medication whose active ingredient is Pramipexole, a synthetic compound classified as a non-ergot dopamine agonist. This medication's core function is built upon its ability to chemically mimic the neurotransmitter dopamine in the central nervous system, a mechanism that is clinically recognized for addressing conditions linked to dopamine signaling irregularities.

As a dopamine agonist, Pramipexole acts by directly stimulating specific dopamine receptors in the brain, particularly the D2 and D3 subtypes, thereby substituting for the natural messenger. The substance is a single-entity product and a non-ergot derivative, which is pharmacologically differentiated from older agonist classes. This fundamental correction of the chemical balance is the essential step for achieving its general therapeutic benefit in conditions such as primary movement disorders.

The Significance of the Extended-Release Formulation (Mirapex LA/ER)

The designation LA (Long-Acting) or ER (Extended-Release) indicates that this medicine is supplied as a controlled-release tablet intended for oral administration. This specialized form is engineered with a solid matrix that regulates the pace at which the active substance, Pramipexole, is absorbed into the bloodstream.

This extended-release formulation is supported by extensive research demonstrating its capacity to release the drug slowly and steadily over approximately 24 hours. This continuous, stable delivery, which is a key differentiating factor from immediate-release formulations, aims to provide sustained stimulation of the target receptors and is associated with maintaining a more uniform effect across the full day and night cycle with the convenience of once-daily administration.

What side effects are possible with Mirapex LA?

Possible side effects and safety information

The safety profile of Mirapex LA (pramipexole extended-release) is formally documented in regulatory safety classifications, grouping adverse reactions by both frequency and the physiological systems affected. These categories reflect data collected from clinical studies and post-marketing surveillance.

Adverse Reaction Frequencies

Side effects are categorized by the regulatory bodies based on their observed frequency. Very Common reactions (occurring in 10% or more of patients) include nausea and dyskinesia (when used with levodopa). Common reactions (occurring in 1% to less than 10% of patients) include somnolence (drowsiness), dizziness, headache, insomnia, constipation, vomiting, fatigue, hallucinations, and orthostatic hypotension.

System-Organ Classes and Less Common Effects

Adverse events are grouped into System-Organ Classes (SOC) such as Nervous System Disorders and Psychiatric Disorders. Less common effects, classified as Uncommon, include syncope (fainting), confusion, paranoia, delusions, restlessness, and Impulse Control Disorders (e.g., pathological gambling or hypersexuality).

Serious Safety Considerations

Specific serious safety signals are noted in regulatory labeling. These include the potential for sudden, unexpected sleep onset (sleep attacks) during daily activities and post-marketing reports related to heart failure. A documented safety consideration upon rapid dose reduction or discontinuation is the risk of dopamine agonist withdrawal syndrome.

Population and Duration-Related Safety Patterns

The official labeling highlights that certain effects, such as somnolence and orthostatic hypotension, are more frequently observed at the start of treatment or during dose increases. Furthermore, specific safety considerations are documented for older patients (who may have an increased risk of hallucinations) and those with renal impairment, as the drug's clearance depends heavily on kidney function.

Overdose and Emergency Response

The official regulatory description of Mirapex LA (pramipexole) overdose is based on the exaggeration of the pharmacological effects of the dopamine agonist, which can lead to severe and immediate symptoms.

Documented Overdose Profile

Property	Description (Official Regulatory Statement)
Documented Manifestations	Hypotension (low blood pressure), confusion, hallucinations, and dyskinesia (involuntary, erratic movements).
Physiological Systems	Central Nervous System (CNS) and Cardiovascular System.
Immediate Action Required	Seek immediate medical attention for all suspected cases of overexposure.

Management and Considerations

No specific antidote is known for Pramipexole overdose. Management is defined as symptomatic and supportive treatment to address the clinical manifestations as they occur. This includes necessary procedures to manage the patient's airway, ensure adequate oxygenation and ventilation, and continuous monitoring of cardiac function.

If severe hypotension is present, official guidance states that it should be treated using intravenous fluids or, if needed, a sympathomimetic agent to maintain blood pressure. Due to the drug’s elimination pathway, the official labeling notes that renal impairment may potentially limit its removal from the body, and haemodialysis is not effective for clearance.

This profile guides the emergency response by detailing the expected severe symptoms and confirming the required supportive procedures in the absence of a known reversing agent.

Therapeutic Uses of Mirapex LA

What Mirapex LA treats: main uses and benefits

Mirapex LA is an extended-release formulation of pramipexole, a medication that acts as a dopamine agonist. By mimicking the effects of dopamine in the brain, it helps to manage symptoms associated with specific neurological conditions.

Parkinson’s Disease

The primary use of Mirapex LA is for the treatment of the signs and symptoms of Parkinson’s disease. This is a progressive disorder of the nervous system that affects movement, often resulting from a decrease in dopamine-producing cells in the brain.

Mirapex LA is utilized in two main stages of the condition:

Early-stage Parkinson’s disease: It can be used as a standalone treatment (monotherapy) to manage initial symptoms.
Advanced-stage Parkinson’s disease: It may be used in combination with other medications, such as levodopa, to help control symptoms as the condition progresses.

Symptom Management and Benefits

As an extended-release medication, Mirapex LA is designed to provide a steady release of the active ingredient over a 24-hour period. This delivery method focuses on maintaining consistent levels of the medication in the bloodstream, which can assist in the ongoing management of motor symptoms.

The benefits of treatment typically center on the improvement of daily motor functions, including:

Reduction of Tremors: Helping to decrease involuntary shaking or trembling in the limbs.
Improvement in Bradykinesia: Addressing the slowness of movement that often characterizes the condition.
Management of Rigidity: Helping to reduce muscle stiffness and Improve flexibility.
Postural Stability: Assisting with balance and coordination issues.

By addressing these symptoms, the medication aims to support the individual’s ability to perform routine physical activities and maintain functional mobility.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mirapex LA?

The population eligibility for using Mirapex LA (pramipexole extended-release) is strictly defined by regulatory labeling from government health authorities, focusing on age, organ function, and medical history.

Official Eligibility Constraints

Population Group	Eligibility Status (Regulatory Wording)
Approved Age Group	Established for Adults only.
Pediatric Population	Not established (under 18 years); use is not recommended.
Absolute Contraindication	Known hypersensitivity to pramipexole or any excipients.
Renal Impairment (Severe)	Generally not recommended (creatinine clearance < 30 mL/min).
Pregnancy and Lactation	Use is not recommended due to potential risks and effects on lactation.

Use of Mirapex LA is contraindicated if a patient has a known allergy to the active substance pramipexole or any other component of the tablet. The medicine is formally established only for adults with Parkinson's disease. Its safety and efficacy have not been established in the pediatric population (under 18 years), leading to a not recommended status for children and adolescents. Eligibility is also conditioned by kidney function; patients with severe renal impairment are generally not recommended for use. Furthermore, regulatory guidance states that use is not recommended during both pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mirapex LA (pramipexole extended-release) may interact with certain medicines and substances, which can alter its effectiveness or increase the risk of specific effects. These interactions are primarily categorized based on their mechanism: those that alter the body’s processing of pramipexole and those that have additive or opposing effects on the nervous system.

Clinically Relevant Interactions

Interacting Product Category	Effect on Pramipexole/Patient	Regulatory Constraint/Requirement
Inhibitors of Renal Cationic Secretion (e.g., cimetidine, amantadine)	Decreases the renal clearance of pramipexole, increasing its concentration in the body.	Requires a reduction in the pramipexole dose, especially in patients with impaired kidney function.
Central Nervous System (CNS) Depressants (e.g., sedating medications, alcohol)	Increases the risk of somnolence (drowsiness) and the sudden onset of sleep.	Patients should be advised of the increased risk of sedation and falling asleep while performing daily activities.
Dopamine Antagonists (e.g., certain antipsychotics, metoclopramide)	May counteract the effect of pramipexole by blocking dopamine receptors.	May result in reduced efficacy of pramipexole.

Co-administration with levodopa does not typically require a dose change of pramipexole, but it may require careful adjustment of the levodopa dose. The primary regulatory requirement across these interactions is to monitor the patient for either symptoms of overexposure or loss of efficacy and to adjust the pramipexole dose accordingly when co-administered with medicines that reduce its clearance.

Mechanism of Action

Direct Activation of Dopamine Receptors

This medication functions as a dopamine agonist, meaning it directly binds to and activates specific dopamine receptors (primarily D2 and D3) on nerve cells within the central nervous system (CNS). By mimicking the action of the brain's natural neurotransmitter, this mechanism immediately initiates signaling in key neuronal pathways. The selective binding to and activation of these postsynaptic receptors restores or enhances the dopaminergic signal transduction cascade.

Modulating Central Motor Control Signaling

The activation of these receptors enhances dopaminergic signaling within the CNS, particularly in circuits that govern movement, like the nigrostriatal pathway. This action influences the activity within the central nervous system circuits that process and regulate physical movement. The engagement of these mechanisms modulates the degree of activity within the targeted dopaminergic signaling pathways, producing a measurable physiological response by altering the signal output from these pathways.

Dosage and Administration Information

How Mirapex LA is Used: Administration Guidelines

Mirapex LA (pramipexole extended-release) is a prescription medication administered according to standardized instructions to ensure a proper long-acting effect. The guidance below outlines the administration, dosage, and adjustment patterns.

Administration and Dosing

The route of administration for Mirapex LA is oral, and it is supplied as an extended-release tablet.

Dosing Feature	Instruction
Frequency	Once daily administration.
Starting Dose	Typically 0.375 mg once daily.
Maximum Dose	4.5 mg once daily.
Intake Context	May be taken with or without food.

Procedural Instructions

To preserve the long-acting properties of the medication, the extended-release tablet must be swallowed whole. Tablets should not be chewed, crushed, or divided. Dosage adjustment, known as titration, is performed gradually; the dose may be increased no more frequently than every 5 to 7 days until the maintenance dose is reached.

Population-Specific Adjustments

Specific dose adjustments are required for patients with reduced kidney function. The dose is lowered based on calculated creatinine clearance to prevent accumulation. For individuals with severe renal impairment, the use of the extended-release formulation is generally not recommended.

If treatment is to be stopped, the dose must be tapered off gradually under medical supervision to avoid discontinuation symptoms. If a dose is missed, it should be skipped, and the next dose should be taken at the regularly scheduled time.

Recent Clinical Evidence

Research Examining Idiopathic Parkinson's Disease (PD)

Research into Mirapex LA (pramipexole extended-release) has primarily focused on its use in adults with idiopathic Parkinson's Disease (PD). This research has explored how the medication compares to a placebo (an inactive substance) and, in some cases, how it compares to the immediate-release form of the same medication. These studies are typically structured as Randomized Controlled Trials (RCTs), where researchers are exploring how symptoms change over time when Mirapex LA was monitored. The key areas of focus in these trials are outcomes related to daily functioning or activity level.

Studies in Early Parkinson's Disease

In the context of early PD, where patients were not receiving levodopa, Mirapex LA was evaluated in studies exploring short-term symptom changes. Research examined its use as the only therapy (monotherapy) for conditions marked by functional limitations. The initial controlled trials typically observed patients over a short-term period. Research reports measurements of motor function on standardized scales (like the UPDRS) within the observed populations. Research provides context but not individual predictions, describing the symptom changes monitored in the groups studied over these defined time intervals.

Studies in Advanced Parkinson's Disease

For conditions where symptoms may vary in intensity and are characterized by fluctuating manifestations, studies were conducted in patients already receiving levodopa. In these research scenarios, Mirapex LA was studied as an add-on or "adjunctive" therapy. These studies monitored outcomes reflecting daily functioning or activity level, with a particular focus on how the overall amount of levodopa prescribed (Levodopa Equivalent Daily Dose) changed during the study.

What the Research Does Not Yet Fully Characterize

While research has monitored the drug in both early and advanced PD, certain aspects remain uncertain. Long-term effects are not fully established because the follow-up durations in the most definitive, controlled trials were limited. The level of certainty remains low regarding very long-term effects; the controlled data reflects only short-term monitoring. The question of outcomes specifically related to the extended-release form's long-term use versus the immediate-release form remains an area where comparative evidence is limited in large, multi-year controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Mirapex LA (FAQ)

Q: What is the maximum approved starting dose for Mirapex LA?

According to the official product prescribing information, the recommended starting dose for the treatment of Parkinson’s disease is 0.375 mg once daily. The precise schedule and dose adjustments should be determined by the prescriber.

Q: How should I store Mirapex LA, and for how long?

Regulatory documents outline specific storage conditions, requiring the medication to be kept at a controlled room temperature (between 20 C to 25 C or 68 F to 77 F), protected from light and moisture. While these conditions are specified to maintain the drug’s effectiveness, the exact shelf life or expiration date is not a universally published fact and depends on the specific packaging and dispensing date.

Q: Which specific conditions is Mirapex LA approved to treat?

Official information indicates that Mirapex LA (pramipexole extended-release) is indicated for treating the signs and symptoms associated with Parkinson's disease. A healthcare professional is responsible for determining if the medication is appropriate based on individual patient needs.

Q: Can I cut or crush the Mirapex LA tablets?

No, the extended-release tablets must be swallowed whole. Regulatory instructions strictly advise against chewing, crushing, or dividing the tablets. This is to preserve the long-acting properties of the medication.

Q: Can Mirapex LA be prescribed for Restless Legs Syndrome (RLS)?

The extended-release formulation of pramipexole (Mirapex LA/ER) is officially indicated only for Parkinson's disease. Regulatory documents state that it is not approved for the treatment of Restless Legs Syndrome (RLS); only the immediate-release version of pramipexole has the RLS indication.

Q: What is the recommended titration schedule for Mirapex LA?

Regulatory guidelines describe a specific titration, or dose adjustment, schedule. The official dosing plan indicates that the dose may be increased gradually, typically no more frequently than every 5 to 7 days, following increments as determined by a healthcare professional.

Q: Does taking Mirapex LA cause weight gain or weight loss?

Official safety data gathered during clinical trials mention changes in appetite and weight as possible adverse reactions that have been reported during treatment with this medication. It is a documented effect that may occur, as these effects do not occur in all patients.

Q: What is the difference in side effects between Mirapex LA and the immediate-release version?

Studies and official information indicate that the safety profiles for the extended-release and immediate-release formulations are generally similar for most common side effects. The extended-release formulation was not associated with any new or unexpected safety issues compared to the immediate-release version.

How should Mirapex LA be stored and disposed of?

How to Store and Dispose of Mirapex LA (Pramipexole Extended-Release)

Storage Requirements

Mirapex LA tablets must be kept at controlled room temperature, specifically between 20°C to 25°C (68°F to 77°F). It is mandatory to protect the medicine from light, moisture, and excess heat, and it must be kept from freezing.

Container and Safety: The product must remain in its original container, which should be tightly closed. A critical requirement is to store the medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or outdated Mirapex LA must not be stored and should be discarded. Official regulatory guidance requires asking a healthcare professional or pharmacist about the proper disposal of any unused medicine. If a take-back program is unavailable, non-flushable product can be mixed with an undesirable substance and sealed before being placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z